A Phase 1 interventional study of 4-MUST in Chronic Cholecystitis and Biliary Dyskinesia, sponsored by Valenta Pharm JSC. Recruiting at 1 site in Russia. Open to participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-06-15.
Sponsored by Valenta Pharm JSC · Phase 1, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This open-label study will evaluate the effect of food on the bioavailability of a single dose of 4-MUST, tablets, 128 mg. Additionally, the study will assess the pharmacokinetics, safety, and tolerability of 4-MUST, tablets, 128 mg following both single and multiple oral dose administration.
Valenta Pharm JSC is the lead sponsor of 40 studies on the registry; 18 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Noninclusion Criteria:
Exclusion criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cohort 1, Group 1 (sequence AB) will receive 3 tablets (384 mg) of the study drug under fasting conditions in Period I and under fed conditions in Period II.
Drug: 4-MUST
Cohort 1, Group 2 (sequence AB)will receive 3 tablets (384 mg) of the study drug under fed conditions in Period I and under fasting conditions in Period II.
Drug: 4-MUST
Cohort 2, Multiple dose: 3 tablets (384 mg) three times daily, 30 minutes before meals, for 3 consecutive days (with the last dose taken in the morning of Day 4).
Drug: 4-MUST
128 mg tablets containing trimebutine 4-methylumbelliferyl sulfate (4-MUST)
Also known as: trimebutine 4-methylumbelliferyl sulfate
Pharmacokinetics - Cmax
Maximum plasma concentration (Cmax) of 4-MUST metabolites: trimebutine, N-desmethyltrimebutine, 3,4,5-trimethoxybenzoic acid, 4-methylumbelliferone sulfate, 4-methylumbelliferone and 4-methylumbelliferone glucuronide
Time frame: From 0 to 48 hours (days 1-3 and 8-10)
Pharmacokinetics - tmax
Time to reach Cmax (tmax) of trimebutine, N-desmethyltrimebutine, 3,4,5-trimethoxybenzoic acid, 4-methylumbelliferone sulfate, 4-methylumbelliferone and 4-methylumbelliferone glucuronide
Time frame: From 0 to 48 hours (days 1-3 and 8-10)
Pharmacokinetics - AUC0-t
Area under the plasma concentration-time curve from time 0 to t (AUC0-t) of trimebutine, N-desmethyltrimebutine, 3,4,5-trimethoxybenzoic acid, 4-methylumbelliferone sulfate, 4-methylumbelliferone and 4-methylumbelliferone glucuronide
Time frame: From 0 to 48 hours (days 1-3 and 8-10)
Pharmacokinetics - AUC0-inf
Area under the plasma concentration-time curve from time 0 to infinity (AUC0-inf) of trimebutine, N-desmethyltrimebutine, 3,4,5-trimethoxybenzoic acid, 4-methylumbelliferone sulfate, 4-methylumbelliferone and 4-methylumbelliferone glucuronide
Time frame: From 0 to 48 hours (days 1-3 and 8-10)
Pharmacokinetics - AUC ratio
The ratio of the area under the concentration-time curve over the observation time to the calculated area under the concentration-time curve from zero to infinity
Time frame: From 0 to 48 hours (days 1-3 and 8-10)
Pharmacokinetics - t1/2
Elimination half-life (t1/2) of trimebutine, N-desmethyltrimebutine, 3,4,5-trimethoxybenzoic acid, 4-methylumbelliferone sulfate, 4-methylumbelliferone and 4-methylumbelliferone glucuronide
Time frame: From 0 to 48 hours (days 1-3 and 8-10)
Pharmacokinetics - kel
Elimination constant (kel) of of trimebutine, N-desmethyltrimebutine, 3,4,5-trimethoxybenzoic acid, 4-methylumbelliferone sulfate, 4-methylumbelliferone and 4-methylumbelliferone glucuronide
Time frame: From 0 to 48 hours (days 1-3 and 8-10)
Pharmacokinetics - MRT
Mean residence time (MRT) of of trimebutine, N-desmethyltrimebutine, 3,4,5-trimethoxybenzoic acid, 4-methylumbelliferone sulfate, 4-methylumbelliferone and 4-methylumbelliferone glucuronide
Time frame: From 0 to 48 hours (days 1-3 and 8-10)
Pharmacokinetics - Vd
Volume of distribution of trimebutine, N-desmethyltrimebutine, 3,4,5-trimethoxybenzoic acid, 4-methylumbelliferone sulfate, 4-methylumbelliferone and 4-methylumbelliferone glucuronide
Time frame: From 0 to 48 hours (days 1-3 and 8-10)
Pharmacokinetics - Cmax/AUC0-t
The ratio of the maximum concentration to the area under the concentration-time curve during the observation period
Time frame: From 0 to 48 hours (days 1-3 and 8-10)
Pharmacokinetics - f'
f' - relative bioavailability (AUC(0-t)(fed)/AUC(0- t)(fasting))
Time frame: From 0 to 48 hours (days 1-3 and 8-10)
Pharmacokinetics - f''
f'' is the relative absorption rate (Cmax(fed)/Cmax(fasting))
Time frame: From 0 to 48 hours (days 1-3 and 8-10)
Bioavailability - ratio of Cmax
Ratio of geometric mean Cmax for trimebutine, N-desmethyltrimebutine, 3,4,5-trimethoxybenzoic acid, 4-methylumbelliferone sulfate, 4-methylumbelliferone and 4-methylumbelliferone glucuronide under fasted and fed conditions (with 90% confidence intervals)
Time frame: From 0 to 48 hours (days 1-3 and 8-10)
Bioavailability - ratio of AUC0-t
Ratio of geometric mean AUC0-t for of trimebutine, N-desmethyltrimebutine, 3,4,5-trimethoxybenzoic acid, 4-methylumbelliferone sulfate, 4-methylumbelliferone and 4-methylumbelliferone glucuronide under fasted and fed conditions (with 90% confidence intervals)
Time frame: From 0 to 48 hours (days 1-3 and 8-10)
Bioavailability - ratio of AUC0-inf
Ratio of geometric mean AUC0-inf for of trimebutine, N-desmethyltrimebutine, 3,4,5-trimethoxybenzoic acid, 4-methylumbelliferone sulfate, 4-methylumbelliferone and 4-methylumbelliferone glucuronide under fasted and fed conditions (with 90% confidence intervals)
Time frame: From 0 to 48 hours (days 1-3 and 8-10)
Pharmacokinetics (multiple dosing) - number of terminal timepoints
number of points in the terminal logarithmic phase used to estimate the terminal elimination rate constant of of trimebutine, N-desmethyltrimebutine, 3,4,5-trimethoxybenzoic acid, 4-methylumbelliferone sulfate, 4-methylumbelliferone and 4-methylumbelliferone glucuronide
Time frame: From 72 to 120 hours
Pharmacokinetics (multiple dosing) - Cmax
Maximum plasma concentration (Cmax) of trimebutine, N-desmethyltrimebutine, 3,4,5-trimethoxybenzoic acid, 4-methylumbelliferone sulfate, 4-methylumbelliferone and 4-methylumbelliferone glucuronide
Time frame: From 72 to 120 hours
Pharmacokinetics (multiple dosing) - tmax
Time to reach Cmax (tmax) of trimebutine, N-desmethyltrimebutine, 3,4,5-trimethoxybenzoic acid, 4-methylumbelliferone sulfate, 4-methylumbelliferone and 4-methylumbelliferone glucuronide
Time frame: From 72 to 120 hours
Pharmacokinetics (multiple dosing) - AUC0-t
Area under the plasma concentration-time curve from time 0 to t (AUC0-t) of trimebutine, N-desmethyltrimebutine, 3,4,5-trimethoxybenzoic acid, 4-methylumbelliferone sulfate, 4-methylumbelliferone and 4-methylumbelliferone glucuronide
Time frame: From 72 to 120 hours
Pharmacokinetics (multiple dosing) - AUC0-inf
Area under the plasma concentration-time curve from time 0 to infinity (AUC0-inf) of trimebutine, N-desmethyltrimebutine, 3,4,5-trimethoxybenzoic acid, 4-methylumbelliferone sulfate, 4-methylumbelliferone and 4-methylumbelliferone glucuronide
Time frame: From 72 to 120 hours
Pharmacokinetics (multiple dosing) - AUCextr
Extrapolated AUC of trimebutine, N-desmethyltrimebutine, 3,4,5-trimethoxybenzoic acid, 4-methylumbelliferone sulfate, 4-methylumbelliferone and 4-methylumbelliferone glucuronide
Time frame: From 72 to 120 hours
Pharmacokinetics (multiple dosing) - t1/2
Elimination half-life (t1/2) of trimebutine, N-desmethyltrimebutine, 3,4,5-trimethoxybenzoic acid, 4-methylumbelliferone sulfate, 4-methylumbelliferone and 4-methylumbelliferone glucuronide
Time frame: From 72 to 120 hours
Pharmacokinetics (multiple dosing) - kel
Elimination constant (kel) of trimebutine, N-desmethyltrimebutine, 3,4,5-trimethoxybenzoic acid, 4-methylumbelliferone sulfate, 4-methylumbelliferone and 4-methylumbelliferone glucuronide
Time frame: From 72 to 120 hours
Pharmacokinetics (multiple dosing) - MRT
Mean residence time (MRT) of trimebutine, N-desmethyltrimebutine, 3,4,5-trimethoxybenzoic acid, 4-methylumbelliferone sulfate, 4-methylumbelliferone and 4-methylumbelliferone glucuronide
Time frame: From 72 to 120 hours
Pharmacokinetics (multiple dosing) - Vd
Volume of distribution of trimebutine, N-desmethyltrimebutine, 3,4,5-trimethoxybenzoic acid, 4-methylumbelliferone sulfate, 4-methylumbelliferone and 4-methylumbelliferone glucuronide
Time frame: From 72 to 120 hours
Pharmacokinetics (multiple dosing) - CL
Clearance (CL) of trimebutine, N-desmethyltrimebutine, 3,4,5-trimethoxybenzoic acid, 4-methylumbelliferone sulfate, 4-methylumbelliferone and 4-methylumbelliferone glucuronide
Time frame: From 72 to 120 hours
Pharmacokinetics (multiple dosing) - Cmax,ss
Maximum plasma concentration at steady state of trimebutine, N-desmethyltrimebutine, 3,4,5-trimethoxybenzoic acid, 4-methylumbelliferone sulfate, 4-methylumbelliferone and 4-methylumbelliferone glucuronide
Time frame: From 0 to 72 hours
Pharmacokinetics (multiple dosing) - tmax,ss
Time to reach maximum plasma concentration at steady state of trimebutine, N-desmethyltrimebutine, 3,4,5-trimethoxybenzoic acid, 4-methylumbelliferone sulfate, 4-methylumbelliferone and 4-methylumbelliferone glucuronide
Time frame: From 0 to 72 hours
Pharmacokinetics (multiple dosing) - tmin,ss
Time to reach minimum plasma concentration at steady state of trimebutine, N-desmethyltrimebutine, 3,4,5-trimethoxybenzoic acid, 4-methylumbelliferone sulfate, 4-methylumbelliferone and 4-methylumbelliferone glucuronide
Time frame: From 0 to 72 hours
Pharmacokinetics (multiple dosing) - Cmin,ss
Minimum plasma concentration at steady state of trimebutine, N-desmethyltrimebutine, 3,4,5-trimethoxybenzoic acid, 4-methylumbelliferone sulfate, 4-methylumbelliferone and 4-methylumbelliferone glucuronide
Time frame: From 0 to 72 hours
Pharmacokinetics (multiple dosing) - Cavg,ss
Average plasma concentration at steady state of trimebutine, N-desmethyltrimebutine, 3,4,5-trimethoxybenzoic acid, 4-methylumbelliferone sulfate, 4-methylumbelliferone and 4-methylumbelliferone glucuronide
Time frame: From 0 to 72 hours
Pharmacokinetics (multiple dosing) - CL,ss
Clearance at steady state of trimebutine, N-desmethyltrimebutine, 3,4,5-trimethoxybenzoic acid, 4-methylumbelliferone sulfate, 4-methylumbelliferone and 4-methylumbelliferone glucuronide
Time frame: From 0 to 72 hours
Adverse event type
Adverse events will be assessed by complaints, results of physical examination, results of heart rate and blood pressure assessment, results of respiratory rate assessment, body temperature, laboratory monitoring (clinical blood count, biochemical blood count, urinalysis), electrocardiography; adverse events will be classified in accordance to MedDRA.
Time frame: From day -14 - day -1 (screening) to day 16 ± 1 (end of the study)
Adverse event frequency
Number and frequency of adverse events registered during the study
Time frame: From day -14 - day -1 (screening) to day 16 ± 1 (end of the study)
Adverse event severety
Severity of adverse events registered during the study, assessed using the Common Terminology Criteria for Adverse Events (CTCAE)
Time frame: From day -14 - day -1 (screening) to day 16 ± 1 (end of the study)
Drop-outs associated with adverse events
The number of cases of early termination of participation in the study due to the development of adverse events and/or serious adverse events associated with the study drug
Time frame: From day -14 - day -1 (screening) to day 16 ± 1 (end of the study)
Physical examination results - cardiovascular system
An assessment of the condition of the cardiovascular system on physical examination (normal condition or list of abnormal conditions, if any)
Time frame: From day -14 - day -1 (screening) to day 16 ± 1 (end of the study)
Physical examination results - respiratory system
An assessment of the condition of the respiratory system on physical examination (normal condition or list of abnormal conditions, if any)
Time frame: From day -14 - day -1 (screening) to day 16 ± 1 (end of the study)
Physical examination results - digestive tract
An assessment of the condition of the digestive tract on physical examination (normal condition or list of abnormal conditions, if any)
Time frame: From day -14 - day -1 (screening) to day 16 ± 1 (end of the study)
Physical examination results - endocrine system
An assessment of the condition of the endocrine system on physical examination (normal condition or list of abnormal conditions, if any)
Time frame: From day -14 - day -1 (screening) to day 16 ± 1 (end of the study)
Physical examination results - musculoskeletal system
An assessment of the condition of the musculoskeletal system on physical examination (normal condition or list of abnormal conditions, if any)
Time frame: From day -14 - day -1 (screening) to day 16 ± 1 (end of the study)
Physical examination results - nervous system
An assessment of the condition of the nervous system on physical examination (normal condition or list of abnormal conditions, if any)
Time frame: From day -14 - day -1 (screening) to day 16 ± 1 (end of the study)
Physical examination results - sensory systems
An assessment of the condition of the sensory systems on physical examination (normal condition or list of abnormal conditions, if any)
Time frame: From day -14 - day -1 (screening) to day 16 ± 1 (end of the study)
Physical examination results - skin/visible mucous membranes
An assessment of the condition of the skin/visible mucous membranes on physical examination (normal condition or list of abnormal conditions, if any)
Time frame: From day -14 - day -1 (screening) to day 16 ± 1 (end of the study)
Physical examination results - genitourinary system
An assessment of the condition of the genitourinary system on physical examination (normal condition or list of abnormal conditions, if any)
Time frame: From day -14 - day -1 (screening) to day 16 ± 1 (end of the study)
Safety and Tolerability: vital signs - systolic blood pressure
Systolic blood pressure (SBP, mmHg)
Time frame: From day -14 - day -1 (screening) to day 16 ± 1 (end of the study)
Safety and Tolerability: vital signs - diastolic blood pressure
Diastolic blood pressure (DBP, mmHg)
Time frame: From day -14 - day -1 (screening) to day 16 ± 1 (end of the study)
Safety and Tolerability: vital signs - heart rate
Heart rate (HR, bpm)
Time frame: From day -14 - day -1 (screening) to day 16 ± 1 (end of the study)
Safety and Tolerability: vital signs - respiratory rate
Respiratory rate (breaths per minute)
Time frame: From day -14 - day -1 (screening) to day 16 ± 1 (end of the study)
Safety and Tolerability: vital signs - body temperature (Celsius temperature scale)
Body temperature (Celsius temperature scale)
Time frame: From day -14 - day -1 (screening) to day 16 ± 1 (end of the study)
Safety and Tolerability: 12-lead electrocardiogram (ECG) - heart rate
12-lead ECG (I, II, III, aVR-enhanced unipolar abduction from the right arm , aVL-enhanced unipolar abduction from the left arm, aVF - enhanced unipolar abduction from the left leg, V1-V6): heart rate (beats per minute)
Time frame: From day -14 - day -1 (screening) to day 16 ± 1 (end of the study)
Safety and Tolerability: 12-lead electrocardiogram (ECG) - PQ interval
12-lead ECG (I, II, III, aVR-enhanced unipolar abduction from the right arm , aVL-enhanced unipolar abduction from the left arm, aVF - enhanced unipolar abduction from the left leg, V1-V6): PQ interval (is the period, measured in milliseconds, that extends from the beginning of the P wave (the onset of atrial depolarization) until the beginning of the QRS complex)
Time frame: From day -14 - day -1 (screening) to day 16 ± 1 (end of the study)
Safety and Tolerability: 12-lead electrocardiogram (ECG) - QRS complex
12-lead ECG (I, II, III, aVR-enhanced unipolar abduction from the right arm , aVL-enhanced unipolar abduction from the left arm, aVF - enhanced unipolar abduction from the left leg, V1-V6) taken while lying down: QRS complex (the QRS complex is the combination of three of the graphical deflections seen on a typical electrocardiogram)
Time frame: From day -14 - day -1 (screening) to day 16 ± 1 (end of the study)
Safety and Tolerability: 12-lead electrocardiogram (ECG) - QT interval
12-lead ECG (I, II, III, aVR-enhanced unipolar abduction from the right arm , aVL-enhanced unipolar abduction from the left arm, aVF - enhanced unipolar abduction from the left leg, V1-V6) taken while lying down: QT interval (distance from the beginning of the QRS complex to the end of the T wave)
Time frame: From day -14 - day -1 (screening) to day 16 ± 1 (end of the study)
Safety and Tolerability: clinical blood test - hemoglobin
Hemoglobin (g/L)
Time frame: From day -14 - day -1 (screening) to day 16 ± 1 (end of the study)
Safety and Tolerability: clinical blood test - hematocrit
Hematocrit (%)
Time frame: From day -14 - day -1 (screening) to day 16 ± 1 (end of the study)
Safety and Tolerability: clinical blood test - red blood cell count
Red blood cell count (cells/L)
Time frame: From day -14 - day -1 (screening) to day 16 ± 1 (end of the study)
Safety and Tolerability: clinical blood test - platelet count
Platelet count (cells/L)
Time frame: From day -14 - day -1 (screening) to day 16 ± 1 (end of the study)
Safety and Tolerability: clinical blood test - leukocyte count
Leukocyte count (cells/L)
Time frame: From day -14 - day -1 (screening) to day 16 ± 1 (end of the study)
Safety and Tolerability: clinical blood test - erythrocyte sedimentation rate
Erythrocyte sedimentation rate (mm/h)
Time frame: From day -14 - day -1 (screening) to day 16 ± 1 (end of the study)
Safety and Tolerability: clinical blood test - myelocytes
Leukocyte formula (myelocytes, %)
Time frame: From day -14 - day -1 (screening) to day 16 ± 1 (end of the study)
Safety and Tolerability: clinical blood test - band neutrophils
Leukocyte formula (band neutrophils, %)
Time frame: From day -14 - day -1 (screening) to day 16 ± 1 (end of the study)
Safety and Tolerability: clinical blood test - segmented neutrophils
Leukocyte formula (segmented neutrophils, %)
Time frame: From day -14 - day -1 (screening) to day 16 ± 1 (end of the study)
Safety and Tolerability: clinical blood test - eosinophils
Leukocyte formula (eosinophils, %)
Time frame: From day -14 - day -1 (screening) to day 16 ± 1 (end of the study)
Safety and Tolerability: clinical blood test - basophils
Leukocyte formula (basophils, %)
Time frame: From day -14 - day -1 (screening) to day 16 ± 1 (end of the study)
Safety and Tolerability: clinical blood test - monocytes
Leukocyte formula (monocytes, %)
Time frame: From day -14 - day -1 (screening) to day 16 ± 1 (end of the study)
Safety and Tolerability: clinical blood test - lymphocytes
Leukocyte formula (lymphocytes, %)
Time frame: From day -14 - day -1 (screening) to day 16 ± 1 (end of the study)
Safety and Tolerability: blood chemistry - glucose
Glucose concentration (mmol/L)
Time frame: From day -14 - day -1 (screening) to day 16 ± 1 (end of the study)
Safety and Tolerability: blood chemistry - cholesterol
Total cholesterol concentration (mmol/L)
Time frame: From day -14 - day -1 (screening) to day 16 ± 1 (end of the study)
Safety and Tolerability: blood chemistry - total protein
Total protein in blood serum (g/L)
Time frame: From day -14 - day -1 (screening) to day 16 ± 1 (end of the study)
Safety and Tolerability: blood chemistry - bilirubin
Total bilirubin concentration (micromol/L)
Time frame: From day -14 - day -1 (screening) to day 16 ± 1 (end of the study)
Safety and Tolerability: blood chemistry - creatinine
Creatinine concentration (micromol/L)
Time frame: From day -14 - day -1 (screening) to day 16 ± 1 (end of the study)
Safety and Tolerability: blood chemistry - alkaline phosphatase
Alkaline phosphatase activity (U/L)
Time frame: From day -14 - day -1 (screening) to day 16 ± 1 (end of the study)
Safety and Tolerability: blood chemistry - alanine transaminase
Alanine transaminase activity (U/L)
Time frame: From day -14 - day -1 (screening) to day 16 ± 1 (end of the study)
Safety and Tolerability: blood chemistry - aspartate transaminase
Aspartate transaminase activity (U/L)
Time frame: From day -14 - day -1 (screening) to day 16 ± 1 (end of the study)
Safety and Tolerability: urinalysis - specific gravity
Specific gravity of the urine
Time frame: From day -14 - day -1 (screening) to day 16 ± 1 (end of the study)
Safety and Tolerability: urinalysis - color
Color of the urine
Time frame: From day -14 - day -1 (screening) to day 16 ± 1 (end of the study)
Safety and Tolerability: urinalysis - transparency
Transparency of the urine
Time frame: From day -14 - day -1 (screening) to day 16 ± 1 (end of the study)
Safety and Tolerability: urinalysis - pH
pH of the urine
Time frame: From day -14 - day -1 (screening) to day 16 ± 1 (end of the study)
Safety and Tolerability: urinalysis - protein
Protein concentration (g/L)
Time frame: From day -14 - day -1 (screening) to day 16 ± 1 (end of the study)
Safety and Tolerability: urinalysis - glucose
Glucose concentration (mmol/L)
Time frame: From day -14 - day -1 (screening) to day 16 ± 1 (end of the study)
Safety and Tolerability: urinalysis - red blood cells
Red blood cell content (number in sight)
Time frame: From day -14 - day -1 (screening) to day 16 ± 1 (end of the study)
Safety and Tolerability: urinalysis - white blood cells
White blood cell content (number in sight)
Time frame: From day -14 - day -1 (screening) to day 16 ± 1 (end of the study)
Safety and Tolerability: urinalysis - casts
Presence of casts (Yes/No)
Time frame: From day -14 - day -1 (screening) to day 16 ± 1 (end of the study)
Safety and Tolerability: urinalysis - mucus
Presence of mucus (Yes/No)
Time frame: From day -14 - day -1 (screening) to day 16 ± 1 (end of the study)
Safety and Tolerability: urinalysis - bacteria
Presence of bacteria (Yes/No)
Time frame: From day -14 - day -1 (screening) to day 16 ± 1 (end of the study)
Started Jan 2026 (actual). Primary completion is estimated for Jun 2027, 17 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Biliary Dyskinesia